# Enjamb

> Enjamb (YC P26) builds full-stack AI agents for biopharma R&D that run a drug program from discovery through FDA approval. Its agents sit on top of legacy pharma systems - Benchling, Veeva, Medidata, SAS - with no migration, doing the work across clinical evidence, trial design, statistical programming, and regulatory submissions while keeping a visible source-to-submission trail. Founded in 2025 by Rayan Mubarak and Maadhav Deekshitha, the San Francisco company raised a $650K pre-seed and says its platform was used by 500+ employees at major pharma firms within weeks of launch.

- **Founded:** 2025
- **Headquarters:** San Francisco, California, United States
- **Founders:** Rayan Mubarak (CEO & Co-founder), Maadhav Deekshitha (CTO & Co-founder)
- **Team size:** 2-3
- **Products:** Enjamb agentic workspace, Legacy-system connection layer, FDA submission generation
- **Notable:** Accepted into Y Combinator's P26 (Spring 2026) batch., Raised a $650K pre-seed from Y Combinator and Founders Inc., Reported 500+ users across major pharma companies within weeks of launch.

## Products & services

- **Enjamb agentic workspace** — Browser-based workspace with Word, Excel, PowerPoint editors and sandboxed Python/R environments, where AI agents execute scientific and regulatory work across clinical evidence, trial design, statistical programming and submissions.
- **Legacy-system connection layer** — An integration layer that lets agents act on top of Benchling, Veeva, Medidata and SAS with no data migration, keeping every source, tool call, code run and document change attached to its output for review.
- **FDA submission generation** — Automated assembly of regulatory submission packages, with claims of 48-hour turnaround versus roughly 8 months and 98% first-pass FDA compliance on generated datasets.

## Achievements

- Accepted into Y Combinator's P26 (Spring 2026) batch.
- Raised a $650K pre-seed from Y Combinator and Founders Inc.
- Reported 500+ users across major pharma companies within weeks of launch.
- Claims 48-hour FDA submission package generation versus ~8 months, and 98% first-pass FDA compliance.
- Founder Rayan Mubarak has a first-author cancer-ML publication in JMIR reported to outperform state-of-the-art by 20%.

## Latest updates

- **2026-04** — Announced $650K pre-seed backed by Y Combinator and Founders Inc.
- **2026-05** — Y Combinator highlighted Enjamb building full-stack AI agents for biopharma R&D; reported 500+ pharma users.

## Links

- Website: https://enjamb.ai
- LinkedIn: https://www.linkedin.com/company/enjamb
- Twitter/X: https://x.com/enjamblabs

---

Profile page: https://yespress.io/enjamb-yc-p26
Published by YesPress — https://yespress.io
Last updated: 2026-07-31